Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle for 18 Months

NCT02537067 is registered in ClinicalTrials.gov with Cellontech Co., Ltd. as lead sponsor.

NCT NCT02537067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle for 18 Months
Lead sponsor
Cellontech Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2010
Completion date
November 30, 2015
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ankle (ligaments); instability, familial, defect of articular cartilage, degenerative joint disease of ankle and/or foot